Investing News NetworkOctober 24, 2023 TCT 2023: Medtronic adds to the body of evidence for Evolut TAVR with late-breaking clinical trial data from the Evolut Low Risk Trial Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced four-year results from the Evolut Low Risk Trial.

投资新闻网络2023年10月24日TCT 2023:Medtronic为Evolut TAVR增加了证据体系，Evolut低风险试验Medtronic plc（NYSE:MDT）是全球医疗技术领导者，最近的临床试验数据今天公布了Evolut低风险试验的四年成果。

The Medtronic Evolut™ transcatheter aortic valve replacement (TAVR) system demonstrated exceptional outcomes and sustained valve performance, proven by significantly better hemodynamics than surgical aortic valve replacement (SAVR). Only Evolut TAVR has reported consistently lower and diverging rates of death or disabling stroke versus state-of-the-art surgery, at four years.

美敦力Evolut™ 经导管主动脉瓣置换术（TAVR）系统表现出优异的结果和持续的瓣膜性能，血流动力学显着优于手术主动脉瓣置换术（SAVR）。只有Evolut TAVR在四年内报告的死亡率或致残性卒中与最先进的手术相比持续下降和分歧。

The data were presented at the 35 th Transcatheter Cardiovascular Therapeutics (TCT) conference, the annual scientific symposium of the Cardiovascular Research Foundation and simultaneously published in the Journal of the American College of Cardiology . Since the approval of TAVR in low-risk surgical patients, there is an ongoing need for evidence to better understand the intermediate and longer-term durability of TAVR devices of different designs.

这些数据在第35届经导管心血管治疗（TCT）会议，心血管研究基金会年度科学研讨会上发表，同时发表在美国心脏病学会杂志上。自从TAVR在低风险手术患者中获得批准以来，仍然需要证据来更好地理解不同设计的TAVR设备的中期和长期耐用性。

'As we see patients in the Evolut Low Risk trial continue to show positive outcomes and sustained valve performance compared to surgery out to four years, this helps us establish intermediate-term evidence for Evolut TAVR and helps define what this might look like in the long term,' said Dr. Michael Reardon , Allison Family Distinguished Chair of Cardiovascular Research and professor of cardiothoracic surgery at the Houston Methodist Hospital and principal investigator of the trial.

“正如我们所看到的，与手术相比，Evolut低风险试验中的患者在长达四年的时间里继续显示出积极的结果和持续的瓣膜表现，这有助于我们为Evolut TAVR建立中期证据，并有助于确定长期的情况“迈克尔·雷登博士说，Allison家族杰出的心血管研究主席和休斯顿卫理公会医院心胸外科教授以及该试验的首席研究员。

'These results are not only encouraging, but pivotal in shaping treatment decisions for low-risk patients with symptomatic severe aortic stenosis. We are seeing sustai.

“这些结果不仅令人鼓舞，而且对于有症状的严重主动脉瓣狭窄的低风险患者形成治疗决策至关重要。我们正在看到sustai。